Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Vertex Pharmaceuticals Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Net fixed asset turnover
Net fixed asset turnover (including operating lease, right-of-use asset)
Total asset turnover
Equity turnover

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The investment activity ratios demonstrate varying trends over the observed period. Generally, the ratios indicate a shift in asset utilization efficiency, particularly when considering operating leases. The net fixed asset turnover ratio, excluding operating leases, consistently increased from 7.18 in March 2022 to 8.68 in March 2024, before experiencing a decline to 7.89 by December 2025. Conversely, the net fixed asset turnover ratio including operating leases exhibited a different pattern, initially increasing but then declining more substantially, falling from 5.53 in March 2022 to 3.89 in December 2025.

Net Fixed Asset Turnover (Excluding Operating Lease)
This ratio shows a clear upward trend from March 2022 through March 2024, suggesting increasing efficiency in generating revenue from fixed assets. The subsequent decline from March 2024 to December 2025 indicates a potential decrease in this efficiency, possibly due to increased investment in fixed assets without a corresponding increase in revenue, or a decrease in revenue. The magnitude of the decline is moderate.
Net Fixed Asset Turnover (Including Operating Lease)
The inclusion of operating lease assets significantly alters the turnover picture. While an initial increase is observed, the ratio experiences a more pronounced and consistent decline beginning in March 2024. This suggests that the utilization of assets acquired through operating leases is becoming less efficient, or that the value of these assets is not translating into proportional revenue generation. The drop from 6.86 in March 2024 to 3.89 in December 2025 is substantial and warrants further investigation.
Total Asset Turnover
The total asset turnover ratio demonstrates a generally decreasing trend from 0.56 in March 2022 to a low of 0.43 in December 2023. A slight recovery to 0.47 by December 2025 is observed, but the ratio remains below the initial value. This indicates a decreasing ability to generate revenue from all assets held by the company. The fluctuations are relatively small, suggesting a gradual shift rather than a dramatic change.
Equity Turnover
The equity turnover ratio generally decreased from 0.73 in March 2022 to 0.64 in June 2023, then increased to 0.70 in March 2024, before declining again to 0.64 in December 2025. This suggests a fluctuating relationship between revenue generated and the amount of equity invested in the business. The changes are less dramatic than those observed in the net fixed asset turnover ratio including operating leases, indicating a more stable relationship between revenue and equity.

In summary, the analysis reveals a divergence in asset utilization trends depending on whether operating lease assets are included. While the core fixed asset turnover shows moderate changes, the inclusion of operating leases highlights a significant decline in efficiency. The total asset turnover and equity turnover ratios suggest a more gradual shift in overall asset and equity utilization.


Net Fixed Asset Turnover

Vertex Pharmaceuticals Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
Property and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Net fixed asset turnover = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ Property and equipment, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The net fixed asset turnover ratio demonstrates a generally increasing trend over the observed period, with some quarterly fluctuations. Initially, the ratio stood at 7.18 and exhibited growth through the first half of 2023, peaking at 8.59 in September 2023. A slight decrease followed in December 2023, before rising again to 9.51 in September 2024, representing the highest value in the series. The ratio then decreased in the final quarter of 2024 and continued to decline through the first three quarters of 2025, ending at 7.89.

Overall Trend
The overall trend indicates increasing efficiency in generating revenue from fixed assets over much of the period. However, the most recent quarters show a reversal of this trend, suggesting a potential decrease in asset utilization efficiency.
Growth Phase (Mar 31, 2022 – Sep 30, 2023)
From March 2022 to September 2023, the ratio consistently increased, moving from 7.18 to 8.59. This suggests that the company was becoming more effective at utilizing its property, plant, and equipment to generate sales. The growth was not linear, with slightly slower increases observed between June and September 2022, and between March and June 2023.
Peak and Subsequent Decline (Sep 30, 2024 – Dec 31, 2025)
The ratio reached its peak of 9.51 in September 2024. Following this peak, a downward trend is observed, with the ratio decreasing to 7.89 by December 2025. This decline could be attributed to several factors, including an increase in fixed assets without a corresponding increase in revenue, or a decrease in revenue. Further investigation would be needed to determine the underlying cause.
Relationship to Revenues and Fixed Assets
The ratio’s fluctuations correlate with changes in both revenues and net property, plant, and equipment. Revenue generally increased throughout the period, contributing to the initial rise in the ratio. However, the more substantial increase in fixed assets in the later quarters, coupled with a slower revenue growth rate, appears to be driving the recent decline in the ratio.

In summary, while the company demonstrated improving efficiency in utilizing fixed assets for a significant portion of the analyzed period, recent trends suggest a potential weakening of this efficiency. Monitoring this ratio closely in future periods will be important to understand whether this decline is temporary or indicative of a more sustained shift.


Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Vertex Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
 
Property and equipment, net
Operating lease assets
Property and equipment, net (including operating lease, right-of-use asset)
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ Property and equipment, net (including operating lease, right-of-use asset)
= ( + + + ) ÷ =


The net fixed asset turnover ratio, calculated using property and equipment net of accumulated depreciation and including operating lease right-of-use assets, demonstrates a generally increasing trend from March 31, 2022, through September 30, 2023, followed by a notable decline. Revenues also generally increased over the period, but the rate of increase in fixed assets exceeded that of revenue in the latter part of the observed timeframe.

Overall Trend
From March 31, 2022, to September 30, 2023, the net fixed asset turnover ratio increased from 5.53 to 6.73. This indicates improving efficiency in generating revenue from the company’s fixed assets. However, beginning with the December 31, 2023, reporting period, the ratio began to decrease, falling to 3.89 by December 31, 2025.
Initial Growth Phase (Mar 31, 2022 – Sep 30, 2023)
The ratio experienced consistent growth during this period. The most significant increase occurred between June 30, 2023, and September 30, 2023, moving from 6.57 to 6.73. This suggests a period of efficient asset utilization alongside revenue growth.
Decline Phase (Dec 31, 2023 – Dec 31, 2025)
A clear downward trend is observed from December 31, 2023, onward. The ratio decreased from 6.79 to 3.89 over the course of nine quarters. This decline coincides with a substantial increase in property and equipment, net, suggesting that the company has been investing heavily in fixed assets, but revenue growth has not kept pace. The largest single decrease occurred between March 31, 2024, and June 30, 2024, falling from 6.86 to 5.84.
Revenue and Asset Relationship
Revenues increased from US$2,097.5 million in March 31, 2022, to US$3,190.0 million in December 31, 2025. However, property and equipment, net, increased more substantially, from US$1,436.4 million to US$3,083.0 million over the same period. This disparity explains the observed decline in the net fixed asset turnover ratio, indicating that the company is becoming less efficient at generating revenue per dollar of fixed assets.

The observed trend suggests a shift in the company’s investment strategy, potentially involving significant capital expenditures. Further investigation into the nature of these investments and their expected returns would be necessary to fully understand the implications of this changing ratio.


Total Asset Turnover

Vertex Pharmaceuticals Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Total asset turnover = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The total asset turnover ratio for the analyzed period demonstrates a generally declining trend, followed by a slight stabilization and then a minor increase. Initially, the ratio decreased from 0.56 in March 2022 to 0.43 in December 2022, indicating a progressively less efficient use of assets to generate revenue. This trend continued into the first half of 2023, reaching a low of 0.47 in June 2023.

Overall Trend
A consistent downward trend in the total asset turnover ratio is evident from March 2022 through December 2022. This suggests the company required increasingly larger asset bases to achieve the same level of revenue. The ratio then stabilized between 0.47 and 0.51 for the subsequent seven quarters, indicating a potential leveling off of this inefficiency. A slight increase to 0.47 is observed in the final quarter analyzed.
Short-Term Fluctuations
A minor increase in the ratio is observed between December 2023 (0.43) and March 2024 (0.51). This could be attributed to a temporary increase in revenue relative to assets, or a reduction in the asset base. However, this increase was not sustained, with the ratio decreasing slightly in June 2024 before stabilizing again.
Recent Performance
The most recent four quarters (March 2024 – December 2025) show a relatively stable ratio fluctuating between 0.47 and 0.49. This suggests that the company’s asset utilization has reached a plateau, and further improvements in efficiency may require significant changes in operational strategy or asset management.
Long-Term Implications
The sustained decline in the ratio from 2022 to mid-2023 warrants attention. While the recent stabilization is encouraging, continued monitoring is necessary to determine if this represents a genuine shift in asset utilization or merely a temporary pause in the downward trend. A consistently low asset turnover ratio may indicate overinvestment in assets, inefficient operations, or a need to divest underperforming assets.

In summary, the analysis reveals a period of decreasing asset efficiency followed by a period of relative stability. The company’s ability to improve its total asset turnover ratio in the future will likely depend on its strategic decisions regarding asset allocation and operational improvements.


Equity Turnover

Vertex Pharmaceuticals Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
Shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Equity turnover = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ Shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The equity turnover ratio for the analyzed period demonstrates a generally decreasing trend, followed by a recent stabilization and slight increase. Initially, the ratio declined from 0.73 in March 2022 to a low of 0.56 in December 2022. This suggests a diminishing ability to generate revenue relative to shareholder equity during that timeframe. The ratio remained relatively stable through the first half of 2023, continuing the downward trend to 0.61 in June 2023, before showing signs of recovery.

Overall Trend
A consistent decline in equity turnover was observed from the first quarter of 2022 through the fourth quarter of 2022. This indicates that the company was becoming less efficient in utilizing shareholder equity to generate sales. However, the ratio began to stabilize and then increase in the latter part of the analyzed period.
Recent Performance (2023-2025)
From September 2023 through December 2024, the equity turnover ratio fluctuated between 0.58 and 0.70. A notable increase to 0.70 was recorded in December 2024, suggesting improved efficiency in revenue generation relative to equity. This trend continued into the first half of 2025, with the ratio reaching 0.68 in September 2025, before decreasing slightly to 0.64 in December 2025.
Equity and Revenue Relationship
The initial decline in equity turnover coincided with increasing shareholder equity and relatively stable revenue. This suggests that equity growth outpaced revenue growth during that period. The subsequent stabilization and increase in the ratio, however, indicate a more balanced relationship between equity and revenue, with revenue growth beginning to catch up to, and in some instances, exceed the growth in shareholder equity.

The fluctuations in the equity turnover ratio warrant continued monitoring. While the recent trend suggests a potential improvement in the company’s efficiency in utilizing equity, the ratio remains below its initial level from March 2022. Further investigation into the drivers of these changes, including revenue growth strategies and equity management practices, may be beneficial.